Eton Lifts 2026 Revenue Outlook to $145M+ on 99% Q2 Surge
ETON has more than doubled off its 52-week low of $14.27.
Summary
Eton Pharmaceuticals reported Q2 2026 revenue of $37.6 million, up 99% year-over-year, and raised full-year revenue guidance to exceed $145 million. The company also lifted Adjusted EBITDA margin guidance to at least 35%.
Updates
· Reuters — Adjusted EPS was $0.43 versus $0.11 consensus; shares rose about 24% in extended trading.
· SEC 10-Q — Q2 net income was $11.6 million, or $0.35 diluted EPS, versus a $2.6 million loss a year earlier. Six-month revenue was $61.9 million with net income of $13.1 million.
Key Events · Earnings and Guidance · ETON
-
Q2 Revenue Up 99%
Second quarter 2026 revenue reached $37.6 million, up from $18.9 million in Q2 2025, driven by HEMANGEOL and strong portfolio growth.
-
Full-Year Guidance Raised
Management now expects 2026 revenue to exceed $145 million, up from prior guidance of more than $120 million, and Adjusted EBITDA margin of at least 35%, up from 30%.
-
ASN-001 Licensing Payment
A $3 million licensing payment for ASN-001 will be expensed in Q3 2026, impacting near-term profitability.
-
Potential ALKINDI Milestone
A one-time $4 million commercial milestone payment related to ALKINDI SPRINKLE sales may be triggered in Q4 2026.
Analysis · ETON · Life Sciences
A standout second quarter saw revenue climb 99% year-over-year to $37.6 million, swinging the company to a net profit of $11.6 million. Management responded by raising full-year revenue guidance to exceed $145 million, up from $120 million, and lifting Adjusted EBITDA margin guidance to at least 35%. The company also disclosed a $3 million licensing payment for ASN-001 and a potential $4 million milestone payment for ALKINDI SPRINKLE, both of which will affect second-half expenses. With cash of $26.8 million and a strong product portfolio, Eton is executing well, but the raised guidance and milestone payments are material new information for investors.
How filings like this one have moved
In the 30 days to Oct 18, 2026, 37.6% of the 940 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.76%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ETON was trading at $48.07 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.1B. The 52-week trading range was $14.27 to $50.18. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.